GLOW Peptide Stack: GHK-Cu, BPC-157 and TB-500
GLOW is not a compound. It is a packaging decision — three separate peptides lyophilized into one vial and sold under a single name. That distinction matters more than anything else on this page, because the research supporting GLOW is not research on GLOW. It is research on GHK-Cu, plus research on BPC-157, plus research on TB-500, presented as though the three add up. They have never been tested together in any published study.
What is in the vial
The blend sold as GLOW is typically a 70 mg vial in a 5:1:1 ratio:
| Component | Amount | Share of vial | Best available evidence |
|---|---|---|---|
| GHK-Cu | 50 mg | 71% | Strong in-vitro collagen data; one randomised human trial of the topical form, largely negative on objective endpoints; no human data for injection |
| BPC-157 | 10 mg | 14% | Extensive rodent literature on gut and tendon healing; no controlled human trial |
| TB-500 | 10 mg | 14% | Animal data on the parent protein thymosin β4; the fragment sold as TB-500 has not been through human trials |
The GHK-Cu dominance is the whole positioning argument. GHK-Cu is the component with a cosmetic literature behind it, so a vial that is 71% GHK-Cu gets sold as a skin product, while the same three compounds in a repair-weighted ratio would be sold for injury. The ratio is a marketing choice, not a finding.
What the research says about each component
GHK-Cu — the skin claim
The copper tripeptide has a genuinely interesting in-vitro record: it stimulated collagen synthesis in fibroblast cultures in the foundational 1988 work, and later cell studies extended that to glycosaminoglycans and keratinocyte markers. The problem is the step from culture dish to person. The randomised human trial of topical GHK-Cu after CO2 laser resurfacing was largely negative on objective endpoints — the one place the compound was properly tested in people, it did not deliver what the cell data promised. For the injected form there is no human trial at all.
BPC-157 — the repair claim
Deep rodent literature on gastric ulcers, tendon healing and nerve regeneration, and essentially no controlled human research. The unresolved question is angiogenesis: a compound that promotes new blood vessel growth is not neutral in the presence of an undiagnosed tumor. That is stated as unresolved, not as safe.
TB-500 — the borrowed evidence
Most impressive-sounding TB-500 citations are studies of thymosin β4, the full parent protein that reached human trials. TB-500 is a synthetic fragment of it. Evidence about the parent protein is not evidence about the fragment, and this substitution is the most common error in peptide marketing.
The dosing problem a blend vial creates
A fixed-ratio vial removes a decision you would otherwise make. Once the ratio is 5:1:1, any volume you draw delivers all three in that proportion — so matching one component to its reference range automatically fixes the other two at whatever the ratio dictates. If a protocol's GHK-Cu amount is your anchor, the BPC-157 and TB-500 amounts are decided for you; anchor on BPC-157 instead and the GHK-Cu number moves five-fold. There is no published protocol for the blend to resolve this, because the blend has never been studied.
The same arithmetic trap appears in the two-component version, where using the vial's total labeled mass instead of the per-compound mass halves the intended dose — we cover that in detail on theBPC-157 + TB-500 blend page. Ourreconstitution calculator handles blend vials on a per-compound basis, which is the only way the numbers stay honest.
Formula: concentration = peptide (mcg) ÷ water (ml). Volume = dose ÷ concentration. One unit on a U-100 insulin syringe = 0.01 ml. Values are for laboratory reference only.
Regulatory status
- None of the three components is FDA approved for injection, individually or as a blend.
- GHK-Cu for injectable routes appears on FDA's list of bulk drug substances nominated for compounding and subsequently withdrawn.
- BPC-157 and TB-500 appear on the same withdrawn list. In July 2026 an FDA advisory committee voted in favour of adding both to the 503A compounding list, over FDA staff scientists' objections — a non-binding vote that begins a rulemaking process rather than changing anything immediately. Details on the BPC-157 page.
- WADA prohibits BPC-157 (S0) and thymosin-β4 derivatives including TB-500 (S2.3) for tested athletes.
GLOW Blend — 70 mg (50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500) — American Peptides
Sold as a lyophilized multi-peptide vial for research use. With three compounds in one vial, the per-compound COA matters more than usual — check that the certificate covers each component, not just total mass.
We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.
Frequently asked questions
What is the GLOW peptide stack?
GLOW is a pre-mixed vial containing three peptides sold together: GHK-Cu, BPC-157 and TB-500. The common blend ratio is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 in a single 70 mg vial. The GHK-Cu dominance is what makes it marketed for skin rather than injury recovery.
Is there any research on the GLOW stack?
No study has tested these three compounds in combination — not in humans, not in animals. Every claim made about GLOW is assembled from separate research on each individual component, and combining compounds does not combine their evidence.
What is the GLOW blend dosage?
There is no established dose, because the combination has never been studied. Community protocols reference the individual compound ranges, but a blend vial forces a fixed ratio: drawing a dose that matches one component's reference range automatically fixes the other two, whether or not those amounts make sense. Our calculator handles the per-compound math.
Is GLOW safe?
Unknown, and that is the accurate answer. None of the three components is FDA approved for injection. GHK-Cu injectable appears on FDA's list of substances nominated for compounding and withdrawn. BPC-157 has no controlled human trial. The interaction of the three has never been examined at all.
Why is GHK-Cu the dominant peptide in the blend?
GHK-Cu is the component with the cosmetic literature — collagen synthesis in fibroblast cultures — so a GHK-Cu-heavy ratio supports skin positioning. It is worth knowing that the human trial of topical GHK-Cu was largely negative on objective endpoints, and there is no human data at all for the injected form.
Sources
- Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Letters, 1988;238(2):343–6. PubMed
- Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery, 2006;8(4):252–259 — the randomised human trial; objective endpoints negative. PubMed
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. Journal of Applied Physiology, 2011;110(3):774–80. PubMed
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017;95(3):323–333. PubMed
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005;11(9):421–9. PubMed
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 2026 — reports no study of BPC-157 and TB-500 in combination. PubMed
- FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — lists GHK-Cu (injectable routes), BPC-157 and TB-500 under substances nominated but withdrawn. FDA
- FDA Pharmacy Compounding Advisory Committee, meeting of July 23–24, 2026. Meeting page
- World Anti-Doping Agency. Prohibited List 2026. WADA Prohibited List
Related guides
- GHK-Cu: the copper tripeptide, topical versus injected
- BPC-157: side effects, dosage and evidence
- TB-500: what the thymosin β4 research does and does not show
- BPC-157 + TB-500: the two-component blend and its dosing trap
- Peptide reconstitution calculator